Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | TDO2 | P48775 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18675613 | 1.00 | TSHR (0.50) | TSHRHIF1ATDP1IDO1TDO2 | |
| SCHEMBL18675614 | 1.00 | TSHR (0.50) | TSHRHIF1ATDP1IDO1TDO2 | |
| SCHEMBL683625 | 0.91 | TSHR (0.59) | TSHRHIF1ATDP1IDO1TDO2 | |
| SCHEMBL15586 | 0.85 | TAAR1 (0.48) | TSHRHIF1AADRA2AKDM4ELMNA | |
| SCHEMBL13870614 | 0.83 | ADRB2 (0.56) | TSHRHIF1ATDP1IDO1TDO2 | |
| SCHEMBL15617669 | 0.83 | SLC6A2 (0.49) | TSHRHIF1ATDP1IDO1TDO2 | |
| SCHEMBL17069244 | 0.83 | IDO1 (0.47) | TSHRIDO1TDO2KDM4ECNR1 | |
| SCHEMBL21910185 | 0.82 | TSHR (0.50) | TSHRHIF1ATDP1IDO1TDO2 | |
| SCHEMBL18682149 | 0.81 | IDO1 (0.54) | TSHRHIF1ATDP1IDO1TDO2 | |
| SCHEMBL686394 | 0.81 | IDO1 (0.54) | TSHRHIF1ATDP1IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212222-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | ANYGEN CO., LTD. (KR) | 2023-07-06 | — | — | US | disclosed |
| US-11071749-B2 | Oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-20200339565-A1 | PRODRUG SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2020-10-29 | — | — | US | disclosed |
| US-20200147119-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-05-14 | — | — | US | disclosed |
| US-10344281-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20180223278-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-08-09 | — | — | US | disclosed |
| US-10022371-B2 | Procaspase-activating compounds and methods | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-07-17 | — | — | US | disclosed |
| US-10005732-B2 | Potent non-urea inhibitors of soluble epoxide hydrolase | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005732-B2 | Potent non-urea inhibitors of soluble epoxide hydrolase | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-06-26 | — | — | US | disclosed |
| US-8334290-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334290-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-18 | — | — | US | disclosed |
| US-20120184734-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| US-20120029022-A1 | Potent Non-Urea Inhibitors Of Soluble Epoxide Hydrolase | THE TRUSTEES OF COLUMBIA UNIVESITY IN THE CITY OF NEW YORK (US) | 2012-02-02 | — | — | US | disclosed |
| EP-1954287-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| EP-2230312-A1 | Probe compound for detecting and isolating enzymes and means and methods using the same | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| US-20090264405-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-22 | — | — | US | disclosed |
| US-20090264405-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-22 | — | — | US | disclosed |
| WO-2007070173-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264405-A1 | Cetp Inhibitors | CETP, APOB, PCSK9 | TSHR 3198/4885HIF1A 1663/4885TDP1 860/4885 |
| US-20180223278-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | TSHR 3125/4885HIF1A 3795/4885TDP1 441/4885 |
| US-11071749-B2 | Oligonucleotide analogues targeting human LMNA | LMNB2, LMNA, LMNB1 | TSHR 1863/4885HIF1A 3541/4885TDP1 1439/4885 |
| US-20120184734-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | CNBP, ZC3HAV1, DPP4 | TSHR 3811/4885HIF1A 1387/4885TDP1 307/4885 |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | TSHR 436/4885HIF1A 3618/4885TDP1 2555/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | TSHR 1873/4885HIF1A 409/4885TDP1 2972/4885 |
| US-10344281-B2 | Functionally-modified oligonucleotides and subunits thereof | RTCB, NSUN3, NSUN2 | TSHR 3125/4885HIF1A 3795/4885TDP1 441/4885 |
| US-20200339565-A1 | PRODRUG SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | PREP, UNG, DPP4 | TSHR 3454/4885HIF1A 909/4885TDP1 275/4885 |
| US-10022371-B2 | Procaspase-activating compounds and methods | CASP3, CASP5, CASP6 | TSHR 4827/4885HIF1A 1410/4885TDP1 530/4885 |
| US-20200147119-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | LMNB2, LMNA, LMNB1 | TSHR 1863/4885HIF1A 3541/4885TDP1 1439/4885 |
| US-20120029022-A1 | Potent Non-Urea Inhibitors Of Soluble Epoxide Hydrolase | EPHX1, EPHX2, ECE1 | TSHR 4761/4885HIF1A 470/4885TDP1 3207/4885 |
| US-20230212222-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | GPR119, GPR39, FABP4 | TSHR 3065/4885HIF1A 3228/4885TDP1 4730/4885 |
| US-10005732-B2 | Potent non-urea inhibitors of soluble epoxide hydrolase | EPHX1, EPHX2, ECE1 | TSHR 4761/4885HIF1A 470/4885TDP1 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.